within Pharmacolibrary.Drugs.ATC.N;

model N02BB04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 7.5e-05,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.035,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0035,
    Tlag           = 15.0
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N02BB04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Propyphenazone is a non-opioid analgesic and antipyretic drug of the pyrazolone class. It has been widely used for the treatment of mild-to-moderate pain (including headache and toothache) and fever, though its use has declined or been withdrawn in some countries due to concerns over safety (risk of agranulocytosis). It is currently not approved in many markets.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Volz, M, &amp; Kellner, HM (1980). Kinetics and metabolism of pyrazolones (propyphenazone, aminopyrine and dipyrone). <i>British journal of clinical pharmacology</i> 10 Suppl 2(Suppl 2) 299S–308S. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.1980.tb01813.x\">10.1111/j.1365-2125.1980.tb01813.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7002187/\">https://pubmed.ncbi.nlm.nih.gov/7002187</a></p></li><li><p>Mazzarino, M, et al., &amp; Botrè, F (2010). Effects of propyphenazone and other non-steroidal anti-inflammatory agents on the synthetic and endogenous androgenic anabolic steroids urinary excretion and/or instrumental detection. <i>Analytica chimica acta</i> 657(1) 60–68. DOI:<a href=\"https://doi.org/10.1016/j.aca.2009.10.022\">10.1016/j.aca.2009.10.022</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19951758/\">https://pubmed.ncbi.nlm.nih.gov/19951758</a></p></li><li><p>Neugebauer, M, et al., &amp; Saleh, G (1997). Stereoselective metabolic study of famprofazone. <i>Biomedical chromatography : BMC</i> 11(6) 356–361. DOI:<a href=\"https://doi.org/10.1002/(SICI)1099-0801(199711)11:6&lt;356::AID-BMC692&gt;3.0.CO;2-T\">10.1002/(SICI)1099-0801(199711)11:6&lt;356::AID-BMC692&gt;3.0.CO;2-T</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9413615/\">https://pubmed.ncbi.nlm.nih.gov/9413615</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N02BB04;
